Is a blood test feasible for the detection of Alzheimer's disease?

Video Author: Neurology Today
Published on: 06.16.2014

In a panel discussion, David S. Knopman, MD, FAAN, a professor of neurology at the Mayo Clinic in Rochester, MN; Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN; and Associate Editor Robert Holloway Jr., MD, FAAN, offer an analysis of why a blood test for Alzheimer's disease is needed and the challenges that remain ahead for ensuring that it is accurate. Read the Annual Meeting abstract which inspired the discussion: http://bit.ly/1kqYYIG.

All Videos
Most Viewed
Most Emailed



Creator: Sarah Owens
Duration: 7:02
Results from exome-sequencing suggest lysosomal storage gene variants may predispose some people to PD, according to a new study presented at the AAN Annual Meeting. Brent Fogel, MD, PhD, FAAN, associate professor of neurology and human genetics at University of California, Los Angeles, discusses the possible clinical ramifications — the potential to target lysosomal pathways — with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, MD, FAAN, of the University of Rochester. Read more about the study: http://bit.ly/NT-PDLysosomal.
Creator: Sarah Owens
Duration: 8:06
Results from a meta-analysis presented at the AAN Annual Meeting suggest resuming oral anticoagulation after an ICH decreases mortality risk and results in better outcomes. In a discussion with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, MD, FAAN, of the University of Rochester, Larry B. Goldstein, MD, FAAN, FAHA, chair and professor of neurology at the University of Kentucky, said residual confounding factors among other limitations with this type of analysis must be considered when weighing these findings. Read more about the study: http://bit.ly/NT-AnticoagulationICH.
Creator: Sarah Owens
Duration: 4:55
Sepsis may contribute to the risk of long-term seizures, according to a study presented at this year’s AAN Annual Meeting. Joseph I. Sirven, MD, FAAN, chair and professor of neurology at the Mayo Clinic in Phoenix, AZ, discusses the clinical implications of the study in a discussion with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, of the University of Rochester. Read more about the sepsis and seizures association: http://bit.ly/NT-SepsisSeizures.
Creator: Sarah Owens
Duration: 10:54
The FDA-approved drug, nusinersen, and gene therapy agent, AVXS-101 were both found effective for SMA in studies presented at the AAN Annual Meeting. Brent Fogel, MD, PhD, FAAN, associate professor of neurology and human genetics at University of California, Los Angeles, discusses the underlying pathogenesis of SMA and the difficult clinical decisions that each presents with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, of the University of Rochester. Read more about nusinersen results and the AVXS-101 study: http://bit.ly/NT-NusinersenGeneTherapy.
Creator: Sarah Owens
Duration:
Stenting rates for carotid-artery stenosis have not declined, despite evidence suggesting endarterectomy may be more effective, according to a study reported at the AAN Annual Meeting. In a discussion with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, of the University of Rochester, Larry B. Goldstein, MD, FAAN, FAHA, chair and professor of neurology at the University of Kentucky suggests that each therapy should be compared with medical therapy, and that findings from CREST-2 should provide more information for clinical decision-making. Read more about the study: http://bit.ly/NT-StentingStenosis.
Creator: Sarah Owens
Duration: 8:25

Neurology Today editors interview Kristina Simonyan, MD, PhD, associate professor of neurology and otolaryngology at the Icahn School of Medicine at Mount Sinai, and Serena Bianchi, PhD, a post-doctoral fellow in Dr. Simonyan’s laboratory, about their imaging studies showing structural differences between different phenotypes and genotypes of spasmodic dysphonia.

Read the full story on the study in Neurology Today: http://bit.ly/NT-ANASpasmodicDysphonia.
Creator: Sarah Owens
Duration: 8:12

Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert Holloway, MD, MPH, FAAN, discuss the challenges of measuring the value of neurodiagnostic tests, with a dearth of available data on efficacy.

Read the full story in Neurology Today: http://bit.ly/NT-ANADiagnosticTests.

Creator: Sarah Owens
Duration: 7:07

A meta-analysis of 5 trials found that the procedure was more effective for stroke, the sooner it was performed, but remained effective up to 7.3 hours after symptom onset – significantly longer than the current guideline window of 6 hours. Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert Holloway, MD, MPH, FAAN, discuss what the findings mean for stroke treatment and minimizing time to reperfusion.

Read the full story in Neurology Today: http://bit.ly/NT-ANAEndovascular.

Creator: Sarah Owens
Duration: 12:43

A 5-year follow-up study found that deep brain stimulation (DBS) of the subthalamic nucleus improved motor function for people with early-stage Parkinson’s disease compared to medical treatment alone. The study’s principal investigator David Charles, MD, FAAN, professor and vice chairman of neurology at Vanderbilt Neuroscience Institute, discusses the advantages and complications of treating patients in early stages of the disease with the Neurology Today editors.

Read the full story in Neurology Today: http://bit.ly/NT-DBSEarlyParkinsons.

Creator: Sarah Owens
Duration: 6:33
Over time, medical therapy for unruptured brain arteriovenous malformations (AVMs) led to fewer strokes and deaths than surgical intervention, according to a five-year analysis of data from the randomized ARUBA trial. Vladimir Hachinski, MD, FAAN, professor of neurology at the University of Western Ontario, discusses the clinical ramifications of the new data in this interview with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert G. Holloway Jr., MD, FAAN. Read the Neurology Today article about the study here: http://bit.ly/ARUBA-NT.
Creator: Sarah Owens
Duration: 8:10
Elevated levels of sulfonylurea receptor-1 (SUR1), in cerebrospinal fluid may be a potential biomarker of edema after traumatic brain injury, and slower declines in Sur1 levels is associated with worse clinical status, according to a study by investigators at the University of Pittsburgh Medical Center. Watch as Neurology Today Editor-in-chief Dr. Steven P. Ringel, FAAN, and Associate Editor Dr. Robert G. Holloway Jr., FAAN, discuss the study with Kevin N. Sheth, MD, FAAN, chief, of the division of neurocritical care & emergency neurology at Yale New Haven Hospital. Read the Neurology Today article about the study here: http://bit.ly/SUR1-NT
Creator: Sarah Owens
Duration: 8:10
Optical coherence tomography (OCT), which is used to measure retinal thickness, can help clinicians predict multiple sclerosis (MS) progression two to five years later, according to an international longitudinal cohort study presented at the 2016 AAN Annual Meeting and published in Lancet Neurology. Steven P. Ringel, MD, FAAN, and Associate Editor Dr. Robert G. Holloway Jr., MD, FAAN, discuss the study with Peter Calabresi, MD, FAAN, director of the neuroimmunology division at Johns Hopkins University. Read the Neurology Today article about the study here: http://bit.ly/OCT-MS.
Creator: Sarah Owens
Duration: 8:27
Patients who are treated with tissue plasminogen activator (tPA), or alteplase, treatment for ischemic stroke may not need a routine computed tomography (CT) scan, according to a study by researchers at University of North Carolina. Commenting on the study, Vladimir Hachinski, MD, FAAN, professor of neurology University of Western Ontario, emphasized that doctors should evaluate the need for a CT scan for each patient individually depending on the type of stroke they had. Watch as Neurology Today Editor-in-chief Dr. Steven P. Ringel, FAAN,and Associate Editor Dr. Robert G. Holloway Jr., FAAN, discuss the study with Dr. Hachinski.
Creator: Sarah Owens
Duration: 7:05
Can women with epilepsy get pregnant as easily as healthy women? Yes, according to a new study that challenges conventional wisdom that women with epilepsy have a more difficult time getting pregnant. Watch here as Neurology Today Editor-in-Chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert G. Holloway Jr., MD, FAAN, discuss the implications of the findings with study author Page Pennell, MD, director of research in the epilepsy division at Brigham and Women’s Hospital in Boston. Read the Neurology Today article about the study here: http://bit.ly/NT-fertility.
Creator: Editor
Duration: 9:00
A new study by a team of researchers at the Alzheimer's Disease Center at Rush University Medical Center suggests that diabetes is not associated with the hallmark pathology of Alzheimer's disease. Rather, the data show that cerebrovascular disease — brain infarcts — associated with diabetes can lead to dementia, and that larger infarcts, rather than very small ones, seem to play a role. The Neurology Today editors discuss the findings with Alzheimer's disease expert Steven T. DeKosky, MD, FAAN, deputy director of the McKnight Brain Institute and professor of neurology at the University of Florida.
Creator: Editor
Duration: 8:48
A high-fat diet mouse model induced neuropathy similar to that observed in patients with pre-diabetes and type 2 diabetes. Work with the model suggests that tightly controlling blood glucose is not sufficient to prevent the development or progression of peripheral neuropathy in type 2 diabetes. An emerging concept is that diabetic neuropathy is associated with metabolic syndrome, and not hyperglycemia alone. The Neurology Today editors discuss the model and how it could translate into new research targets for peripheral neuropathy with Eva Feldman, MD, PhD, FAAN, director of the A. Alfred Taubman Medical Research Institute and Program for Neurology Research and Discovery at the University of Michigan.
Creator: Editor
Duration: 8:22
The Neurology Today editors analyze two new studies that track readmission rates among neurology patients in hospitals throughout the US with S. Andrew Josephson, MD, a professor and senior executive vice chair of the University of California, San Francisco.
Creator: Editor
Duration: 8:46
What’s behind the pathological process of proteins misfolding and aggregating in conditions such as Alzheimer’s and multiple system atrophy? The Neurology Today editors analyze insights from two new papers with David M. Holtzman, MD, FAAN, professor and chair of neurology at Washington University School of Medicine in St. Louis.
Creator: Editor
Duration: 6:02
In this video, our editors discuss a new study that suggests that transthyretin could serve as the first gene-specific biomarker for ALS and frontotemporal dementia. Dr. Brent Fogel discusses the findings with Neurology Today Editor-in-chief Dr. Steven Ringel and Associate Editor Dr. Robert Holloway Jr.
Creator: Editor
Duration: 5:46
In this video, our editors discuss a study that investigates the ability of clinicians to predict which patients will go on to develop mild cognitive impairment. Neurology Today Editor-in-chief Dr. Steven Ringel and Associate Editor Dr. Robert Holloway Jr. discuss the findings with Alzheimer’s disease expert Dr. David Gill.



Creator: Sarah Owens
Duration: 7:02
Results from exome-sequencing suggest lysosomal storage gene variants may predispose some people to PD, according to a new study presented at the AAN Annual Meeting. Brent Fogel, MD, PhD, FAAN, associate professor of neurology and human genetics at University of California, Los Angeles, discusses the possible clinical ramifications — the potential to target lysosomal pathways — with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, MD, FAAN, of the University of Rochester. Read more about the study: http://bit.ly/NT-PDLysosomal.
Creator: Sarah Owens
Duration: 8:06
Results from a meta-analysis presented at the AAN Annual Meeting suggest resuming oral anticoagulation after an ICH decreases mortality risk and results in better outcomes. In a discussion with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, MD, FAAN, of the University of Rochester, Larry B. Goldstein, MD, FAAN, FAHA, chair and professor of neurology at the University of Kentucky, said residual confounding factors among other limitations with this type of analysis must be considered when weighing these findings. Read more about the study: http://bit.ly/NT-AnticoagulationICH.
Creator: Sarah Owens
Duration: 4:55
Sepsis may contribute to the risk of long-term seizures, according to a study presented at this year’s AAN Annual Meeting. Joseph I. Sirven, MD, FAAN, chair and professor of neurology at the Mayo Clinic in Phoenix, AZ, discusses the clinical implications of the study in a discussion with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, of the University of Rochester. Read more about the sepsis and seizures association: http://bit.ly/NT-SepsisSeizures.
Creator: Sarah Owens
Duration: 10:54
The FDA-approved drug, nusinersen, and gene therapy agent, AVXS-101 were both found effective for SMA in studies presented at the AAN Annual Meeting. Brent Fogel, MD, PhD, FAAN, associate professor of neurology and human genetics at University of California, Los Angeles, discusses the underlying pathogenesis of SMA and the difficult clinical decisions that each presents with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, of the University of Rochester. Read more about nusinersen results and the AVXS-101 study: http://bit.ly/NT-NusinersenGeneTherapy.
Creator: Sarah Owens
Duration:
Stenting rates for carotid-artery stenosis have not declined, despite evidence suggesting endarterectomy may be more effective, according to a study reported at the AAN Annual Meeting. In a discussion with Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, of the University of Colorado, and Associate Editor Robert G. Holloway, of the University of Rochester, Larry B. Goldstein, MD, FAAN, FAHA, chair and professor of neurology at the University of Kentucky suggests that each therapy should be compared with medical therapy, and that findings from CREST-2 should provide more information for clinical decision-making. Read more about the study: http://bit.ly/NT-StentingStenosis.
Creator: Sarah Owens
Duration: 8:25

Neurology Today editors interview Kristina Simonyan, MD, PhD, associate professor of neurology and otolaryngology at the Icahn School of Medicine at Mount Sinai, and Serena Bianchi, PhD, a post-doctoral fellow in Dr. Simonyan’s laboratory, about their imaging studies showing structural differences between different phenotypes and genotypes of spasmodic dysphonia.

Read the full story on the study in Neurology Today: http://bit.ly/NT-ANASpasmodicDysphonia.
Creator: Sarah Owens
Duration: 8:12

Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert Holloway, MD, MPH, FAAN, discuss the challenges of measuring the value of neurodiagnostic tests, with a dearth of available data on efficacy.

Read the full story in Neurology Today: http://bit.ly/NT-ANADiagnosticTests.

Creator: Sarah Owens
Duration: 12:43

A 5-year follow-up study found that deep brain stimulation (DBS) of the subthalamic nucleus improved motor function for people with early-stage Parkinson’s disease compared to medical treatment alone. The study’s principal investigator David Charles, MD, FAAN, professor and vice chairman of neurology at Vanderbilt Neuroscience Institute, discusses the advantages and complications of treating patients in early stages of the disease with the Neurology Today editors.

Read the full story in Neurology Today: http://bit.ly/NT-DBSEarlyParkinsons.

Creator: Sarah Owens
Duration: 8:10
Elevated levels of sulfonylurea receptor-1 (SUR1), in cerebrospinal fluid may be a potential biomarker of edema after traumatic brain injury, and slower declines in Sur1 levels is associated with worse clinical status, according to a study by investigators at the University of Pittsburgh Medical Center. Watch as Neurology Today Editor-in-chief Dr. Steven P. Ringel, FAAN, and Associate Editor Dr. Robert G. Holloway Jr., FAAN, discuss the study with Kevin N. Sheth, MD, FAAN, chief, of the division of neurocritical care & emergency neurology at Yale New Haven Hospital. Read the Neurology Today article about the study here: http://bit.ly/SUR1-NT
Creator: Sarah Owens
Duration: 8:10
Optical coherence tomography (OCT), which is used to measure retinal thickness, can help clinicians predict multiple sclerosis (MS) progression two to five years later, according to an international longitudinal cohort study presented at the 2016 AAN Annual Meeting and published in Lancet Neurology. Steven P. Ringel, MD, FAAN, and Associate Editor Dr. Robert G. Holloway Jr., MD, FAAN, discuss the study with Peter Calabresi, MD, FAAN, director of the neuroimmunology division at Johns Hopkins University. Read the Neurology Today article about the study here: http://bit.ly/OCT-MS.
Creator: Sarah Owens
Duration: 7:05
Can women with epilepsy get pregnant as easily as healthy women? Yes, according to a new study that challenges conventional wisdom that women with epilepsy have a more difficult time getting pregnant. Watch here as Neurology Today Editor-in-Chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert G. Holloway Jr., MD, FAAN, discuss the implications of the findings with study author Page Pennell, MD, director of research in the epilepsy division at Brigham and Women’s Hospital in Boston. Read the Neurology Today article about the study here: http://bit.ly/NT-fertility.
Creator: Editor
Duration: 8:48
A high-fat diet mouse model induced neuropathy similar to that observed in patients with pre-diabetes and type 2 diabetes. Work with the model suggests that tightly controlling blood glucose is not sufficient to prevent the development or progression of peripheral neuropathy in type 2 diabetes. An emerging concept is that diabetic neuropathy is associated with metabolic syndrome, and not hyperglycemia alone. The Neurology Today editors discuss the model and how it could translate into new research targets for peripheral neuropathy with Eva Feldman, MD, PhD, FAAN, director of the A. Alfred Taubman Medical Research Institute and Program for Neurology Research and Discovery at the University of Michigan.
Creator: Editor
Duration: 8:46
What’s behind the pathological process of proteins misfolding and aggregating in conditions such as Alzheimer’s and multiple system atrophy? The Neurology Today editors analyze insights from two new papers with David M. Holtzman, MD, FAAN, professor and chair of neurology at Washington University School of Medicine in St. Louis.
Creator: Editor
Duration: 6:02
In this video, our editors discuss a new study that suggests that transthyretin could serve as the first gene-specific biomarker for ALS and frontotemporal dementia. Dr. Brent Fogel discusses the findings with Neurology Today Editor-in-chief Dr. Steven Ringel and Associate Editor Dr. Robert Holloway Jr.
Creator: Editor
Duration: 5:46
In this video, our editors discuss a study that investigates the ability of clinicians to predict which patients will go on to develop mild cognitive impairment. Neurology Today Editor-in-chief Dr. Steven Ringel and Associate Editor Dr. Robert Holloway Jr. discuss the findings with Alzheimer’s disease expert Dr. David Gill.
Creator: Editor
Duration: 9:10
In this video, our editors discuss a new evidence-based guideline from the AAN and the American Epilepsy Society that looks at factors that contribute to decisions about whether to treat an unprovoked first seizure in adults with an antiepileptic drug. Study author Dr. Jacqueline French discusses the findings of the review and its implications with Neurology Today Editor-in-chief Dr. Steven Ringel and Associate Editor Dr. Robert Holloway.
Creator: Editor
Duration: 5:17
Writing in the Dec. 9, 2014 issue of Neurology, former AAN President Bruce Sigsbee, MD, and James L. Bernat, MD, FAAN, addressed three core aspects of physician burnout. Here, Neurology Today Editor-in-Chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert G. Holloway Jr., MD, FAAN, discuss the strategies they use to address burnout among faculty at their own institutions.
Creator: Editor
Duration: 5:22
The American Academy of Neurology recently released a position paper on opioid use for chronic noncancer pain, finding that “there is no substantial evidence of pain relief or improved function over long periods of time without incurring serious risk of overdose, dependence, or addiction.” Neurology Today Editor-in-chief Steven P. Ringel, MD, FAAN, and Associate Editor Robert Holloway Jr., MD, FAAN, discuss the paper.
Creator: Neurology Today
Duration: 7:40
In Neurology Today’s annual “Best Advances of 2013” selection, editorial board member James L. Bernat, MD, professor of neurology and medicine at Dartmouth Medical School, chose a paper on important issues in palliative care published in Mayo Clinic Proceedings. Watch a video interview with Neurology Today Editor-in-Chief Steven P. Ringel, MD, and Associate Editor Robert G. Holloway Jr., MD, MPH, as they discuss the differences between palliative care and end-of-life care, primary palliative care versus specialty palliative care, and the cost-effectiveness of offering a palliative care program. See the full “Best Advances of 2013: Picks from the Neurology Today Editorial Advisory Board” article in our Dec. 19 issue: http://bit.ly/IYORLE.
Creator: Neurology Today
Duration: 6:15

Two new developments reported at the 2013 American Neurological Association annual meeting have neuromuscular specialists excited for the first time in a while about potential “breakthroughs” for a disorder that has been difficult to diagnose and treat. In a video interview, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert G. Holloway Jr., MD, discuss what’s known about the clinical phenotype of sporadic inclusion body myositis and how it’s currently diagnosed, as well as the two different “camps” in thinking about its underlying mechanism — whether there is an inflammatory or degenerative process. Hear more about the current standards for treatment and their shortcomings, as well as why the findings from the new report — the increase in thigh muscle volume and the suggestion of additional improvements in function — are potential breakthroughs.

For more discussion, read the Nov. 21 Neurology Today reports from the ANA meeting.

Creator: Neurology Today
Duration: 3:34

At this year’s AAN annual meeting, investigators reported that among the neurodegenerative disorders associated with REM sleep behavior disorder (RBD), 94 percent were synucleinopathies, indicating, experts say, that REM sleep behavior disorder is a highly significant prognostic indicator of future neurodegenerative disease. The findings “argue that part of the selective vulnerability involved with Lewy body disease and with MSA likely involves REM sleep circuitry,” study leader Bradley Boeve, MD, chair of behavioral neurology at the Mayo Clinic in Rochester, MN, told attendees of the plenary at the AAN annual meeting. In a video interview, Neurology Today

Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert G. Holloway, MD, discuss the implications of the study and what to tell patients and their families once REM sleep behavior disorder is diagnosed.

Creator: Neurology Today
Duration: 1:43
From the AAN annual meeting: What is the relationship between obstructive sleep apnea and risk for dementia? David Gill, MD, a cognitive behavioral neurologist at Unit Rehabilitation & Neurology in Rochester, NY, who chose this paper as “noteworthy” from the dementia papers at the AAN annual meeting, offers an analysis of the new data here and what it means for clinicians.
Creator: Neurology Today
Duration: 2:09
From the AAN annual meeting: Investigators pored through eight years of medical records — seven years before the diagnosis of psychogenic nonepileptic seizures (PNES) was made and one year after — and found that the patients’ use of hospitals and clinics decreased dramatically after they were given the proper diagnosis. Watch here as Neurology Today editorial advisory board member Jacqueline A. French, MD, professor of neurology at New York University Comprehensive Epilepsy Center and president of the American Epilepsy Society, discusses what this can mean for clinicians seeing patients with PNES.
Creator: TED
Duration: 18:48
Oliver Sacks, MD, neurologist and author of Hallucinations, presenting a special TED lecture in 2009 on the underlying neurological substrates of Charles Bonnet syndrome, in which visually impaired people experience lucid hallucinations.
See the Dec. 20 issue of Neurology Today for a review of Hallucinations.
Creator: Nature Video
Duration: 4:26
Watch here for an explanation of how scientists can control the behavior of cells simply by switching on a light. The technique, known as optogenetics, is teaching us about everything from how we wake up to how we learn. That's why Nature Methods named optogenetics as its Method of the Year 2010. Read more at nature.com/nmeth/focus/moy2010.
Creator: The American Academy of Neurology
Duration: 3:53
A video demonstration of the Epley maneuver by the American Academy of Neurology. Visit neurology.org/content/70/22/2067.full.pdf for the associated AAN guideline on treating benign paroxysmal positional vertigo (BPPV).